ArticleFrontiers in pharmacology2020

Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China.

Peng-Le Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.